Investigational drug · Phase 2
CR-002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "CR-002"
First trial start
2026
Oct 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CR-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- Gastric/GEJ
- Biliary Tract Cancer (BTC)
- Esophageal Squamous Cell Carcinoma (ESCC)
- Ovarian Cancer
- Endometrial Cancer
- Cervical Cancer Metastatic
- Non-small Cell Lung Cancer (NSCLC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Stomach and esophageal cancer · Head and neck cancer · Cervical cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CR-002" as an intervention, largest first.
Crescent Biopharma, Inc.Industry
NCT07909031 · 219 participants (planned) · Start Oct 21, 2026 · Primary completion Oct 2028
Drug: CR-002 · For: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M); Gastric/GEJ; Biliary Tract Cancer (BTC) and 5 more
Sites: Austin, Texas; Dallas, Texas; Fairfax, Virginia
CSL BehringIndustry
NCT01347190 · 25 participants · Start Apr 2011 · Primary completion Aug 2011
Drug: CR002 Liquid API; Placebo · For: Cystic Fibrosis
Sites: Sofia, Bulgaria; Varna, Bulgaria; Debrecen, Hungary · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- PembolizumabpembroPhase 33 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- EnlituoPhase 32 trials
Taizhou Mabtech Pharmaceutical Co.,Ltd · Colorectal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- MDSY-1240Phase 21 trial
Medsyn Biopharma, LLC · Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.